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Abstract
Background: Different diagnostic criteria limit comparisons between populations in the prevalence of diastolic left
ventricular (LV) dysfunction. We aimed to compare across populations age-specific echocardiographic criteria for
diastolic LV dysfunction as well as their correlates and prevalence.
Methods: We measured the E and A peaks of transmitral blood flow by pulsed wave Doppler and the e’ and a’
peaks of mitral annular velocities by tissue Doppler imaging (TDI) in 2 cohorts randomly recruited in Belgium (n =
782; 51.4% women; mean age, 51.1 years) and in Italy, Poland and Russia (n = 476; 55.7%; 44.5 years).
Results: In stepwise regression, the multivariable-adjusted correlates of the transmitral and TDI diastolic indexes
were similar in the 2 cohorts and included sex, age, body mass index, blood pressure and heart rate. Similarly, cut-
off limits for the E/A ratio (2.5th percentile) and E/e’ ratio (97.5th percentile) in 338 and 185 reference subjects free
from cardiovascular risk factors respectively selected from both cohorts were consistent within 0.02 and 0.26 units
(median across 5 age groups). The rounded 2.5th percentile of the E/A ratio decreased by ~0.10 per age decade in
these apparently healthy subjects. The reference subsample provided age-specific cut-off limits for normal E/A and
E/e’ ratios. In the 2 cohorts combined, diastolic dysfunction groups 1 (impaired relaxation), 2 (possible elevated LV
filling pressure) and 3 (elevated E/e’ and abnormally low E/A) encompassed 114 (9.1%), 135 (10.7%), and 40 (3.2%)
subjects, respectively.
Conclusions: The age-specific criteria for diastolic LV dysfunction were highly consistent across the study
populations with an age-standardized prevalence of 22.4% vs. 25.1%.
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Background
Cardiovascular risk factors underlie the first stage of dia-
stolic heart failure (HF). This stage evolves into asymp-
tomatic left ventricular diastolic dysfunction (LVDD)
characterized by impaired relaxation and increased left
ventricular (LV) stiffness, and finally progresses to
clinically overt diastolic HF [1]. Recently published com-
munity-based studies making use of conventional and
tissue Doppler echocardiographic imaging (TDI)
revealed a high prevalence of LVDD, ranging from
11.1% up to 34.7% [2-8]. In the Flemish Study on Envir-
onment, Genes and Health Outcomes (FLEMENGHO),
the frequency was 27.3% [9]. One issue making the
interpretation of the aforementioned reports difficult is
that the prevalence of LVDD cannot be easily compared,
partially because of differing diagnostic criteria and/or
divergent distributions of cardiovascular risk factors in
the sampled populations (for review see Additional file
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derived age-specific criteria for the classification of
LVDD based on a reference sample. Since the publica-
tion of our previous report, [9] echocardiographic exam-
inations continued in the FLEMENGHO cohort and
started in four centers taking part in the European Pro-
ject on Genes in Hypertension (EPOGH). In the present
study, we compared age-specific echocardiographic cri-
teria for LVDD across populations as well as the corre-
lates and prevalence of this condition. By showing
consistency across populations, we aimed to propose a
diagnostic classification that might be useful in clinical
practice.
Methods
Study participants
From August 1985 until December 2005, we randomly
recruited a family-based population sample from a
geographically defined area in northern Belgium as
described elsewhere [9]. EPOGH recruited participants
from 1999 until 2001. The EPOGH investigators were
trained at the Studies Coordinating Centre, and
applied the same protocol, questionnaires and follow-
up procedures, as used in FLEMENGHO. The FLE-
MENGHO and EPOGH studies received ethical
approval. The initial response rate at enrolment was
61.3% [10,11]. All subjects provided informed consent
in writing.
The FLEMENGHO and EPOGH participants
remained in follow-up. Five centers opted to perform
echocardiographic phenotyping and to assess LV func-
tion by using the new TDI indexes along with classical
pulsed wave Doppler velocities of blood flow. Our cur-
rent study population includes 1287 subjects, who were
examined from June 2005 until September 2009. We
excluded 29 subjects from analysis, because of atrial
fibrillation (n = 12), a pacemaker (n = 2), or because
LVDD could not be reliably determined (n =1 5 ) .T h u s ,
the current analysis included 1258 participants: 782
FLEMENGHO participants (Noorderkempen, Belgium)
and 476 EPOGH subjects from Gdańsk (n = 108) and
Kraków (n = 124), Poland, Mirano, Italy (n = 106), and
Novosibirsk, Russia (n = 138).
Echocardiography
In each center one experienced physician did the ultra-
sound examination, using a Vivid 7 Pro (GE Vingmed,
Horten, Norway), interfaced with a 2.5- to 3.5-MHz
phased-array probe, according to a standardized proto-
col described in detail in previous publications [9]. With
the subjects in partial left decubitus and breathing nor-
mally, the observer obtained images, together with a
simultaneous ECG signal, along the parasternal long and
short axes and from the apical 4-, 2-chamber and long-
axis views. All recordings included at least 5 cardiac
cycles and were digitally stored for off-line analysis.
One experienced observer (TK) analyzed the digitally
stored images, using the EchoPac software, version 4.0.4
(GE Vingmed), averaging three cardiac cycles. The LV
internal diameter and interventricular septal and poster-
ior wall thickness were measured at end-diastole from
the 2-dimensionally guided M-mode tracings according
to the recommendations [12]. When optimal orientation
of M-mode ultrasound beam could not be obtained, the
reader performed linear measurements on correctly
oriented two-dimensional images. End-diastolic LV
dimensions were used to calculate LV mass by an anato-
mically validated formula. LV hypertrophy was a left
ventricular mass index (LVMI) of 125 g/m
2 in men and
110 g/m
2 in women or more. We calculated LV ejection
fraction (EF) from LV end-systolic and end-diastolic
volumes measured from the apical 4- and 2-chambers
views, using the standard biplane Simpson’sm e t h o d .
We measured left atrial (LA) dimensions in 3 orthogo-
nal planes: the parasternal long, lateral, and supero-
inferior axes [13]. LA volume (LAVI) was calculated
using the prolate-elipsoid method [13] and was indexed
to body surface area.
From the transmitral flow signal, we measured peak
early (E) and late (A) diastolic velocities, the E/A ratio
and A flow duration. The duration of PV reversal flow
during atrial systole (AR) was measured from the PV
flow signal. From the pulsed wave TDI recordings, we
measured the early (e’) and late (a’) peak diastolic veloci-
ties of the mitral annulus displacement, and the e’/a’
ratio at the 4 acquisition sites (septal, lateral, inferior,
and posterior). We calculated the E/e’ ratio by dividing
transmitral E peak by e’ averaged from the 4 acquisition
sites. As reported previously, [9] the inter-observer
intra-session reproducibility across the four sampling
sites ranged from 4.48% to 5.34% for e’ velocities and
from 3.96% to 4.52% for a’ velocities.
Other measurements
We administered a standardized questionnaire to collect
detailed information on each subject’s medical history,
smoking and drinking habits, and intake of medications.
The conventional blood pressure was the average of five
consecutive auscultatory readings obtained with the sub-
ject in the seated position. Hypertension was a blood
pressure of at least 140 mmHg systolic or 90 mmHg
diastolic or the use of antihypertensive drugs. Body
mass index (BMI) was weight in kilograms divided by
the square of height in meters. Obesity was a BMI of 30
kg/m
2 or higher. Central obesity was a waist circumfer-
ence of at least 102 cm in men or 88 cm in women.
Diabetes was a fasting blood glucose of 7.0 mmol/L or
higher or the use of antidiabetic agents.
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sured in plasma by a competitive enzymatic immunoas-
say for research use (Biomedica Gruppe, Vienna,
Austria) [14]. NT-proBNP in the EPOGH study was
determined in serum by an electrochemiluminescence
immunoassay Elecsys 2010 (Roche Diagnostics, Indiana-
polis, USA) [14].
To generate a reference sample, we excluded partici-
pants, if one or more of the following conditions were
present: hypertension (FLEMENGHO/EPOGH, n = 323/
211), diabetes (n = 29/25), obesity (n = 143/134), central
obesity (n = 216/144), LV hypertrophy (n = 84/36),
renal failure (n = 4/4) or cardiac diseases (valvular
abnormalities, n = 31/8; myocardial infarction and/or
coronary revascularization, n = 24/6). The number of
subjects in the reference group was 338 in FLEMEN-
GHO, 185 in EPOGH, and 523 in total.
Statistical methods
For database management and statistical analysis, we
used SAS software, version 9.1.3 (SAS Institute, Cary,
NC). We compared means and proportions by means of
a large sample z-test and the c
2-test, respectively. We
performed single and stepwise linear regression to iden-
tify correlates of the Doppler indexes as measured on a
continuous scale. We set the P- v a l u e sf o rv a r i a b l e st o
enter and to stay in the regression models at 0.05. To
obtain 95% confidence intervals of the percentile values
of the E/A distributions, we computed the bootstrap dis-
tribution [15] of the thresholds by randomly resampling
the study population 1000 times with replacement,
using the PROC SURVEYSELECT procedure, as imple-
mented in the SAS software. Because NT-proBNP was
measured by different methods in FLEMENGHO and
EPOGH, we rescaled the values by computing popula-
tion-specific z-scores, which reflect the deviation of each
individual measurement from the population mean.
Results and discussion
Characteristics of participants
The 1258 participants included 666 (52.9%) women, and
534 (42.5%) hypertensive patients of whom 325 (26.0%)
were on antihypertensive drug treatment. Mean age (±
SD) was 48.5 ± 15.7 years. Tables 1 and 2 list the clini-
cal and echocardiographic characteristics of the FLE-
MENGHO and EPOGH participants in the entire study
population and in the reference groups. The participants
were older in FLEMENGHO than in EPOGH. LAVI, LV
wall thickness, LVMI and EF (Table 2) were greater in
FLEMENGHO than in EPOGH participants. Only 11
subjects (0.9%) had an EF less than 50%. The FLEMEN-
GHO participants also had lower E/A and e’/a’ ratios
(Table 2). Additional file 1: Tables S3 and S4 show the
clinical and echocardiographic characteristics of the
EPOGH participants by center.
Determinants of transmitral and TDI velocity ratios
In FLEMENGHO and EPOGH subjects, the E/A and e’/
a’ ratios significantly and independently decreased with
age, BMI, heart rate and diastolic blood pressure (Table
3). Furthermore, the e’/a’ ratio decreased with higher
LVMI in the EPOGH participants. In both cohorts, the
transmitral and mitral annular velocities ratios increased
with systolic blood pressure. The E/e’ ratio increased
with female sex, age, BMI, systolic blood pressure, and
LVMI (Table 3). The E/e’ ratio decreased with higher
diastolic blood pressure and LV length in both studies
and with heart rate in FLEMENGHO participants.
There were no differences in the partial regression coef-
ficients between both studies (P ≥ 0.10).
Transmitral and TDI Doppler indexes in the reference
groups
Additional file 1: Tables S5, S6 and S7 show the age-
specific percentiles of the E/A, e’/a’ and E/e’ ratios, and
LAVI in reference participants free from any cardiovas-
cular disease or risk factors selected from the entire
study population, FLEMENGHO and EPOGH, respec-
tively. There was a significant decline in the E/A and e’/
a’ ratio with age even in the reference group (P <
0.0001), because of significant decreases in E and e’
velocities and increases in A and a’ velocities (Additional
file 1: Table S8). In the reference group (Additional file
1: Table S5), the E/e’ ratio increased with age (P <
0.0001). However, the 97.5 percentile of the E/e’ ratio in
the entire reference group (8.60) approximated to the
8.5 cut-off limit for the normal filling pressure as
observed in invasive studies [16]. In the 523 participants
from the reference group, the 97.5 percentile of LAVI
was 28.3 ml/m
2.
Table 4 shows the 2.5 and 97.5 age-group specific per-
centiles for the transmitral E/A ratio and the 97.5 per-
centiles for E/e’ in all reference subjects and in the
FLEMEMGHO and EPOGH reference groups. Using the
bootstrap approach, we calculated the confidence inter-
vals of the 2.5 or 97.5 percentiles in the combined refer-
ence group by age categories. Next, we rounded these
2.5 and 97.5 age-specific percentiles to the closest inte-
ger value. All of these rounded thresholds fell within the
95% confidence boundaries for the 2.5 and 97.5 age-spe-
cific percentiles of the E/A ratio and the 97.5 percentiles
of the E/e’ ratio in the reference group (Table 4).
Prevalence of LVDD
We combined the mitral inflow and TDI velocities to
classify the stages of LVDD. The first group included
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E/A ratio indicative of impaired relaxation (less than
rounded 2.5 percentile; Table 4), but without evidence
of increased LV filling pressures (E/e’ 8.5). The second
group had mildly-to-moderately elevated LV filling pres-
sure (E/e’ > 8.5), and E/A ratio within the normal age-
specific range (the rounded 2.5 to 97.5 percentile; Table
4). We used the differences in durations between the
mitral A flow and the reverse PV flow during atrial sys-
tole (Ad < ARd + 10) and/or LAVI (28 ml/m
2) to con-
firm possible elevation of the LV filling pressures in
group 2. Group 3 had combined LVDD with an elevated
E/e’ ratio and an abnormally low age-specific E/A ratio.
LVDD groups 1, 2 and 3 included 114 (9.1%), 135
(10.7%), and 40 (3.2%) subjects, respectively. Table 5
presents the prevalence of LVDD by study population,
center, and age group respectively. With standardization
to mean age, there were no differences in the prevalence
of LVDD between the FLEMENGHO and EPOGH
cohorts (22.4% vs. 25.1%; P = 0.09). However, in the
EPOGH participants, the age-standardized prevalence of
LVDD was lower (P < 0.04) in Italian participants
(19.6%) than in the participants from Kraków (25.3%)
and Novosibirsk (32.4%). The clinical and
Table 1 Characteristics of participants
Entire population Reference group
Characteristic FLEMENGHO (n = 782) EPOGH (n = 476) FLEMENGHO (n = 338) EPOGH (n = 185)
Anthropometrics
Women, n (%) 402 (51.4) 265 (55.7) 172 (50.9) 110 (59.8)
Age, y 51.1 ± 15.4 44.5 ± 15.1‡ 42.5 ± 13.1 34.6 ± 11.7‡
Height, cm 168.7 ± 9.46 168.0 ± 9.0 170.4 ± 9.1 168.7 ± 8.76*
Weight, kg 75.4 ± 14.4 76.3 ± 16.4 69.7 ± 11.4 66.1 ± 11.8‡
Body mass index, kg/m
2 26.5 ± 4.31 27.0 ± 5.21 24.0 ± 2.76 23.1 ± 3.2†
Waist circumference, cm 89.9 ± 12.3 89.6 ± 14.1 82.5 ± 9.24 79.2 ± 9.9‡
Systolic pressure, mm Hg 129.5 ± 17.6 130.5 ± 19.9 118.3 ± 9.5 117.1 ± 11.5
Diastolic pressure, mm Hg 79.6 ± 9.46 81.3 ± 12.4* 75.2 ± 7.32 74.1 ± 7.9
Heart rate, beats/minute 60.8 ± 9.63 67.0 ± 10.6‡ 60.3 ± 8.8 66.3 ± 9.5‡
Questionnaire data
Current smoking, n (%) 167 (21.4) 102 (21.9) 98 (29.0) 40 (21.9)
Drinking alcohol, n (%) 312 (39.9) 144 (30.2)‡ 157 (46.4) 43 (23.2)‡
Hypertensive, n (%) 323 (41.3) 211 (44.3) ... ...
Treated for hypertension, n (%) 198 (25.32) 127 (27.2) ... ...
Diabetes, n (%) 29 (3.71) 25 (5.25) ... ...
Values are mean (± SD), or number of subjects (%). *P ≤ 0.05; †P ≤ 0.01; ‡P ≤ 0.001
Table 2 Echocardiographic characteristics of participants
Entire population Reference group
Characteristics FLEMENGHO (n = 782) EPOGH (n = 476) FLEMENGHO (n = 338) EPOGH (n = 185)
Conventional echocardiography
Left atrium volume index, ml/m
2 22.9 ± 6.3 21.0 ± 5.6‡ 20.0 ± 4.3 18.2 ± 3.8‡
LV internal diameter, cm 5.04 ± 0.49 5.00 ± 0.43 4.99 ± 0.43 4.88 ± 0.40†
Interventricular septum, cm 0.98 ± 0.17 0.95 ± 0.16‡ 0.90 ± 0.13 0.85 ± 0.12‡
Posterior wall, cm 0.89 ± 0.14 0.87 ± 0.13* 0.82 ± 0.12 0.79 ± 0.11*
LV mass index, g/m
2 92.5 ± 21.9 87.9 ± 20.4‡ 82.9 ± 15.4 77.9 ± 15.5‡
Ejection fraction,% 68.2 ± 7.4 62.6 ± 5.9‡ 67.1 ± 6.3 61.3 ± 5.5‡
Doppler data
E peak, cm/s 75.4 ± 15.9 71.6 ± 15.3‡ 79.7 ± 14.7 76.1 ± 14.6†
A peak, cm/s 65.0 ± 17.5 58.6 ± 16.8‡ 55.6 ± 12.8 48.4 ± 11.6‡
E/A ratio 1.26 ± 0.48 1.33 ± 0.52† 1.52 ± 0.49 1.66 ± 0.50†
e’ peak#, cm/s 11.4 ± 3.6 11.2 ± 3.6 13.8 ± 3.1 13.7 ± 2.6
a’ peak#, cm/s 10.1 ± 2.1 9.23 ± 2.1‡ 9.37 ± 2.1 8.19 ± 2.0‡
e’/a’ ratio# 1.24 ± 0.64 1.36 ± 0.70† 1.63 ± 0.68 1.84 ± 0.66‡
E/e’ ratio 7.08 ± 2.2 6.88 ± 2.2 5.93 ± 1.2 5.65 ± 1.1†
Values are mean (± SD). # Averaged of septum, lateral, inferior and posterior mitral annulus sites. * P ≤ 0.05; †P≤ 0.01; ‡P ≤ 0.001.
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LVDD group appear in Additional file 1: Tables S9 and
S10, respectively.
NT-proBNP and LV diastolic dysfunction
Figure 1 shows histograms of the logarithmically trans-
formed NT-proBNP levels and the corresponding z-
scores by cohort. Compared to the participants with
normal diastolic function (n = 969, 77.0%), subjects with
elevated LV filling pressure (group 2) had significantly
higher NT-proBNP (z-scores, -0.10 ± 0.94 vs. 0.49 ±
1.11; P < 0.0001), with a similar trend (-0.10 ± 0.94 vs.
0.21 ± 1.06; P=0.007) for those with impaired relaxa-
tion (group 1). However, subjects with normal diastolic
function and those with combined dysfunction (group
3) had similar levels of NT-proBNP (-0.10 ± 0.94 vs.
-0.04 ± 1.11; P=0.76).
Discussion
Epidemiological studies performed in the general popu-
lation provide an unbiased estimation of the prevalence
and prognostic significance of health-related states or
events (LVDD in our study). Epidemiology is highly
regarded in evidence-based medicine for identifying risk
factors for disease and determining optimal treatment
approaches for clinical practice. Because the process of
myocardial remodeling starts before the onset of symp-
toms, we place special emphasis on the detection of sub-
clinical (asymptomatic) LV systolic and diastolic
dysfunction and the timely identification of patients who
are at risk for developing overt HF. Thus, the present
report focused on the prevalence and comparison of
echocardiographic criteria for LVDD between popula-
tions. Mean age of the FLEMENGHO and EPOGH par-
ticipants was 51.1 and 44.5 years and the prevalence of
Table 3 Correlates of the E/A, e’/a’ and E/e’ ratios in stepwise regression by cohort
Parameter Transmitral E/A Averaged TDI e’/a’ E/e’
FLEMENGHO EPOGH FLEMENGHO EPOGH FLEMENGHO EPOGH
R
2 (%) 67.5 65.9 73.6 71.2 49.6 46.2
Adjusted R
2 (%) 67.3 65.4 73.4 70.6 49.0 45.1
Partial regression coefficients
Female (0,1)
ß ± SE 0.064 ± 0.025* 0.084 ± 0.039* 0.62 ± 0.15‡ 0.37 ± 0.19*
Partial r
2 (%) 0.22 0.29 1.4 0.44
Age
(+10 years)
ß ± SE -0.23 ± 0.008‡ -0.24 ± 0.012‡ -0.32 ± 0.009‡ -0.28 ± 0.015‡ 0.38 ± 0.048‡ 0.50 ± 0.068‡
Partial r
2 (%) 53.6 51.4 61.1 54.4 33.6 35.4
BMI
(+1 kg/m
2)
ß ± SE -0.017 ± 0.003‡ -0.011 ± 0.00‡ -0.031 ± 0.003‡ -0.026 ± 0.004‡ 0.093 ± 0.015‡ 0.078 ± 0.017‡
Partial r
2 (%) 2.5 0.78 6.8 6.5 3.1 2.3
HR (+10 beats/minute)
ß ± SE -0.13 ± 0.011‡ -0.13 ± 0.014‡ -0.11 ± 0.013‡ -0.13 ± 0.017‡ -0.16 ± 0.063†
Partial r
2 (%) 9.5 8.6 3.2 4.1 0.46
SBP (+10 mmHg)
ß ± SE 0.025 ± 0.008† 0.030 ± 0.012* 0.044 ± 0.010‡ 0.36 ± 0.045‡ 0.36 ± 0.068‡
Partial r
2 (%) 0.43 0.43 0.7 5.1 4.2
DBP (+10 mmHg)
ß ± SE -0.075 ± 0.013‡ -0.079 ± 0.019‡ -0.12 ± 0.016‡ -0.071 ± 0.017‡ -0.21 ± 0.076† -0.27 ± 0.10†
Partial r
2 (%) 0.97 1.5 1.7 1.7 0.70 0.82
LVMI (+10 g/m
2)
ß±S E -0.025 ± 0.011* 0.16 ± 0.032‡ 0.13 ± 0.049†
Partial r
2 (%) 0.67 1.4 0.49
LV length (+1 cm)
ß±S E -0.53 ± 0.10‡ -0.45 ± 0.13‡
Partial r
2 (%) 3.8 1.8
Values are mutually adjusted partial regression coefficients ± SE. BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure;
LVMI, left ventricle mass index. Significance of the partial regression coefficient: * P < 0.05, †P < 0.01, and ‡P < 0.001. There were no differences between the
partial regression coefficients in two studies (P ≥ 0.10)
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mated were 22.4% and 25.1%, respectively. The key find-
ing was that age-specific cut-off limits for the
transmitral E/A ratio and the threshold for the E/e’
ratio, which we used for the classification of LVDD,
were consistent and reproducible across two indepen-
dently recruited population cohorts. The same also
applied to the correlates of the E/A, e’/a’ and E/e’ ratios.
These observations lend support to the clinical
applicability of the criteria for the classification of
LVDD as proposed in this report.
The reported prevalence of LVDD depends on several
factors, such as the characteristics of the population
under study, imaging techniques, and the criteria
applied to diagnose or to grade LVDD (Additional file 1:
Table S1). Redfield [2] and Abhayaratna [3] used similar,
but not identical pulsed wave Doppler and TDI criteria.
Three studies
4-6 defined LVDD exclusively based on
Table 4 Age-specific percentiles for the E/A and E/e’ ratio in the reference groups
Age group
(years)
FLEMENGHO (n =
338)
EPOGH (n =
185)
All subjects* (n =
523)
95% CI for the age-specific
percentiles
Rounded
limits
Transmitral E/A 2.5 percentile
< 30 1.23 1.23 1.23 1.17 to 1.31 1.20
30-39 1.15 0.98 1.04 0.98 to 1.15 1.00
40-49 0.88 0.95 0.91 0.87 to 0.95 0.90
50-59 0.76 0.78 0.78 0.75 to 0.84 0.80
≥ 60 0.67 0.67 0.67 0.66 to 0.74 0.70
97.5 percentile
< 30 3.22 3.25 3.18 2.87 to 3.25 3.20
30-39 2.82 2.55 2.62 2.39 to 2.93 2.60
40-49 2.36 2.05 2.22 2.04 to 2.51 2.20
50-59 1.61 1.72 1.63 1.55 to 1.72 1.60
≥ 60 1.55 1.28 1.48 1.28 to 1.55 1.50
E/e’ 97.5 percentile
< 30 7.66 7.80 7.66 6.98 to 8.17 8.00
30-39 7.47 8.24 7.47 7.04 to 8.56 8.00
40-49 8.85 8.15 8.52 7.64 to 8.85 8.50
50-59 8.84 8.83 8.84 8.60 to 9.62 9.00
≥ 60 8.99 8.73 8.99 8.73 to 9.00 9.00
* The average of the 2.5 and 97.5 percentiles obtained in the FLEMENGHO and EPOGH cohorts
Table 5 Diastolic function grades by study, center and age group
Diastolic function
Normal function 1 group Impaired relaxation 2 group Elevated LV filling pressure 3 group Combined dysfunction
Study
FLEMENGHO 589 (75.3) 73 (9.3) 93 (11.9) 27 (3.5)
EPOGH 380 (79.8) 41 (8.6) 42 (8.8) 13 (2.8)
Center
Gdask 94 (87.0) 7 (6.5) 6 (5.6) 1 (0.9)
Kraków 103 (83.1) 8 (6.4) 10 (8.1) 3 (2.4)
Mirano 85 (80.2) 9 (8.5) 8 (7.5) 4 (3.8)
Novosibirsk 97 (70.4) 18 (13.0) 18 (13.0) 5 (3.6)
Age group
< 30 183 (96.3) 7 (3.7) ––
30-39 197 (94.3) 10 (4.8) 2 (0.9) –
40-49 206 (91.2) 13 (5.7) 4 (1.8) 3 (1.3)
50-59 240 (74.5) 39 (12.1) 34 (10.6) 9 (2.8)
≥ 60 142 (45.7) 45 (14.5) 96 (30.8) 28 (9.0)
Values are number (%). Impaired relaxation (group 1) indicates low E/A and normal E/e’; possible elevated LV filling pressure (group 2) indicates normal E/A and
high E/e’; combined dysfunction (group 3) indicates low E/A and high E/e’
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applied different combinations of the criteria proposed
by the European Working Group on Diastolic Heart
F a i l u r ei n1 9 9 8[ 1 7 ] .T h ec r i t e r i ap r o p o s e di nt h e
recently published recommendations [18] for the evalua-
tion of LV diastolic function by echocardiography
require further testing for their applicability in the gen-
eral population.
In all aforementioned studies participants were ran-
domly recruited from populations (Additional file 1:
Table S2). Age at recruitment was more than 45 years
in 3 reports [2,4,8] and more than 55 years in the Rot-
terdam Study [5]. The Augsburg study [7] encompassed
an age range from 25 to 75 years, whereas the Canberra
study [3] enrolled only elderly from 60 to 86 years. The
prevalence of hypertension and diabetes ranged from
28.2% to 75.0% and from 3.3% to 54.7%, respectively.
T h ep r e v a l e n c eo fa n yg r a d eo fL V D Dr a n g e df r o m
11.1% in Augsburg [7] to 34.7% (7.3%) in Canberra [3]
(Additional file 1: Table S1). In our current study, the
frequency of any grade of LVDD was 23.0%. This esti-
mate has to be interpreted, keeping in mind that age
averaged 48.6 years (range, 14.2-89.5 years), and the
proportions of women and patients with hypertension
or diabetes mellitus were 42.5%, 42.4% and 3.1%,
respectively.
Our current study showed that 3.5% and 2.8% of the
FLEMENGHO and EPOGH participants had a low E/A
ratio in the presence of an elevated E/e’ ratio. To our
knowledge, this group of patients was not described in
previous reports [2,3] with the exception of our previous
FLEMENGHO report [9]. In the current report, we con-
firmed the existence of this type of LVDD in EPOGH
participants. The underlying mechanisms require clarifi-
cation. Parallel increases in the pressures in the LA and
LV during diastole might contribute to this type of
LVDD.
Recent community-based studies [2,4,19,20] explored
the prognostic role of classical Doppler indexes and the
new TDI-derived parameters. In the Olmsted study [2]
Figure 1 The histograms of the NT-proBNP levels (A, C) and the corresponding z-scores (B, D) by the FLEMENGHO and EPOGH cohort.
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Page 7 of 9mild LVDD (hazard ratio, 8.31; P < 0.001) and moderate
or severe diastolic dysfunction (10.2; P < 0.001) pre-
dicted all-cause mortality, while controlling for age, sex,
and EF. However, in this study, the authors did not
adjust the models for other important cardiovascular
risk factors. In 1036 participants enrolled in the Copen-
hagen City Heart study [19], low systolic and A’ veloci-
ties derived from colour Doppler imaging and averaged
from 16 myocardial segments independently predicted
total mortality [19]. The authors did not explore
whether the new TDI indexes captured prognostic infor-
mation over and beyond classical Doppler measure-
ments of diastolic function as it was shown in previous
studies [4,20]. For instance, In the Cardiovascular Health
Study,[20] the adjusted risk of development of overt HF
was highest at the extremes of the distribution of the
transmitral E/A ratio. In the Strong Heart Study,[4] all-
cause and cardiac mortality had a U-shaped relation
with the E/A ratio.
In the absence of an outcome-driven age-specific diag-
nostic reference frame, averaging the 2.5 and 97.5 per-
centiles for the E/A ratio in subjects free from
cardiovascular diseases included in the FLEMENGHO
and EPOGH cohorts, and rounding the resulting bound-
aries to the closest integer value, produced working defi-
nitions of normal LV diastolic function, which can be
easily remembered. Following this approach, absolute
values for the normal lower limit of the E/A ratio,
would be higher than 1.2, 1.0, 0.9, 0.8, and 0.7 in sub-
jects aged < 30, 30-39, 40-49, 50-59, and > 60 years,
respectively. The lower boundaries of the age-specific
thresholds for the E/A ratio decreased approximately by
0.10 per decade of age. In the FLEMENGHO and
EPOGH studies, the 97.5th percentiles of E/e’ ratio in
the reference groups were 8.6 and 8.5, respectively.
These findings are in line with the data reported from
invasive studies, that an E/e’ ratio of less than 8 accu-
rately predicts normal LV filling pressure [17,21].
Because NT-proBNP values vary with the degree of
LVDD,
23 we also compared the levels of NT-proBNP
among the LVDD groups. In line with our previously
published FLEMENGHO findings,[9] we observed
higher levels in subjects with impaired relaxation pattern
(group 1) and in subjects with elevated LV filling pres-
sure (group 2). However, in subjects who had an ele-
vated E/e’ ratio and an abnormally low age-specific E/A
(group 3), the NT-proBNP levels were not different
from those in subjects with normal LV function.
Our study has to be interpreted within the context of
its potential limitations and strengths. First, the Doppler
blood flow measurements and the TDI velocities are
prone to measurement error. In the present study, one
experienced observer in each center recorded all Dop-
pler images using a common highly standardized
imaging protocol [9]. Furthermore, all digitally stored
images were centrally post-processed by one observer.
Second, because NT-proBNP was measured by different
methods in FLEMENGHO and EPOGH, we reported z-
scores instead of the measured values of NT-proBNP.
However, within cohorts the associations between the
classification of LVDD and circulating NT-proBNP
levels were consistent. Third, the patterns of transmitral
flow and mitral annulus velocities depend to some
extent on the compliance and contractile function of the
left atrium. Thus, the evaluation of diastolic function
using the proposed cut-offs might not be applicable to
patients with sustained atrial fibrillation. Fourth, in con-
tinuous analyses, the correlates of LVDD in two cohorts
were the same and in line with previous reports [3-5].
This observation might be considered as a validation of
our current results.
Conclusions
In conclusion, LVDD has a prevalence of over 20% in
European populations. To classify different grades of
LVDD, we applied age-specific diagnostic thresholds
based on a combination of Doppler velocities ratios
derived from transmitral blood flow and mitral annular
movement. We demonstrated that these thresholds were
consistent and reproducible across population cohorts.
This diagnostic classification needs validation in pro-
spective studies in terms of progression of disease and
as predictor of cardiovascular complications. Data col-
lection to meet these goals is currently in progress in
the FLEMENGHO and EPOGH cohorts.
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